Full history for every metric is available with a Kvantra account
Akili, Inc. (AKLI)
Key financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | 20 | 4 | 1 | 0 | 2 | 2 |
| Operating profit | $m | -64 | -56 | |||||
| Net profit | $m | - | -21 | -26 | -62 | -8 | -59 | -49 |
| EPS reported | $ | -0.76 | -0.61 | |||||
| Operating cashflow per share | $ | -0.74 | -0.74 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.74 | -0.74 | |||||
| Free cash flow | $m | -58 | -49 | |||||
| Net debt | $m | -60 | -51 | |||||
| Book value equity | $m | 59 | 50 | |||||
| Book value per share | $ | 0.75 | 0.64 | |||||
| Number of shares | m | 78.2 | 78.53 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.65 | 0.68 | |||||
| P/S LTM | x | 22.70 | 17.50 | |||||
| P/FCF LTM | x | -0.66 | -0.69 | |||||
| EV/EBITDA LTM | x | 0.39 | 0.37 | |||||
| EV/Sales LTM | x | -13.04 | -8.82 | |||||
| Earnings Yield LTM | % | -156.19% | -175.67% | |||||
| FCF Yield | % | -152.30% | -144.11% | |||||
| Quality | ||||||||
| ROE | % | -101.64% | -70.32% | |||||
| ROIC | % | -85.22% | -85.22% | |||||
| Operating margin | % | -3843.0% | -3843.0% | |||||
| Gross margin | % | 51.19% | 51.19% | |||||
| FCF/Sales | % | -3457.1% | -3457.1% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +419.50% | +426.49% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -3.75 | -3.61 | |||||
| Net Debt/EBITDA | x | 1.06 | 1.06 | |||||
| EBIT/Net interest | x | -27.35 | -27.35 | |||||
| Net debt/market cap | % | -157.44% | -150.38% | |||||
| Net debt/Equity | x | -1.02 | -1.02 | |||||
| Gross debt/equity | x | 0.26 | 0.27 | |||||
Company overview
Akili, Inc. is a digital medicine enterprise focused on developing innovative digital therapies for individuals experiencing cognitive impairments. Its flagship product, EndeavorRx, stands out as a unique video game-based treatment that necessitates a physician's prescription and is specifically engineered to directly target and improve cognitive functioning. This company operates from its headquarters in Boston, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Akili, Inc. (AKLI)
Akili, Inc. is a digital medicine enterprise focused on developing innovative digital therapies for individuals experiencing cognitive impairments. Its flagship product, EndeavorRx, stands out as a unique video game-based treatment that necessitates a physician's prescription and is specifically engineered to directly target and improve cognitive functioning. This company operates from its headquarters in Boston, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free